Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
← catalyst calendarNCT05070845 · readout in 714 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
91estimated
Sites
31
Countries
Australia, Canada, Czechia +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-02-02 | actual | When the study began enrolling |
| Primary completion | 2028-08-02 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-08-02 | estimated | The whole study's end, after follow-up |
| First posted | 2021-10-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Primary Immune Thrombocytopenia
Intervention
- Biological: PF-06835375
Primary outcome
what the primary-completion date above is the date OFProportion of participants with change from baseline of platelet counts
measured baseline through 12 and 16 weeks
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed